1-12 of 12
Ioana Kloos
Close
Sort by
Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Evandro Bezerra, Taha Itani, Kistada Wudhikarn, Miguel-Angel Perales, Yang Yang, Usama Gergis, Ahmed Aribi, LaQuisa C. Hill, Nitin Jain, Jessica T. Leonard, Forat Lutfi, Soyoung Kim, Matthew Bye, Hai-Lin Wang, Tsveta Hadjivassileva, Liana Nikolaenko, Ioana Kloos, Amina Abdeldaim, David Dalton, Hairong Xu, Marcelo Pasquini, Partow Kebriaei
Journal: Blood
Blood (2023) 142 (Supplement 1): 1029.
https://doi.org/10.1182/blood-2023-177693
Published: 2023
Journal Articles

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma

Nora Liebers, Hervé Finel, Dominic Edelmann, Guido Kobbe, Ben-Niklas Bärmann, Yasmina Serroukh, Didier Blaise, Dietrich W. Beelen, Carlos Solano, Maija Itäla-remes, Annoek E.C. Broers, Goda Choi, Nicolaus Kroeger, Jenny Louise Byrne, Jean-Jacques Tudesq, Ana Nunes, Rubina Siddiqi, Elande Baro, Dan Zheng, Ioana Kloos, Peter Dreger, Anna Maria Sureda Balari, Bertram Glass, Sascha Dietrich
Journal: Blood
Blood (2023) 142 (Supplement 1): 3494.
https://doi.org/10.1182/blood-2023-174368
Published: 2023
Journal Articles

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

Andre Goy, Caron A. Jacobson, Ian W. Flinn, Brian T. Hill, Wen-Kai Weng, Luke Mountjoy, Oluwole Olalekan, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 106.
https://doi.org/10.1182/blood-2023-174273
Published: 2023
Journal Articles

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Michael Dickinson, Javier L. Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha K. Kekre, Sven de Vos, Christine Lui, Jacob Wulff, Chad M. Williams, Weixin Peng, Ioana Kloos, Hairong Xu, Sattva S. Neelapu
Journal: Blood
Blood (2023) 142 (Supplement 1): 894.
https://doi.org/10.1182/blood-2023-174510
Published: 2023
Journal Articles

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan O. Oluwole, Patrick M. Reagan, David B. Miklos, Frederick L. Locke, Andre Goy, Caron A. Jacobson, Javier L. Munoz, Edouard Forcade, Max S. Topp, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Marie José Kersten, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2120.
https://doi.org/10.1182/blood-2023-174681
Published: 2023
Journal Articles

Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Javier Munoz, Patrick M. Reagan, Andre H. Goy, David B. Miklos, Dan Zheng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Marie José Kersten, Michael Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9320–9322.
https://doi.org/10.1182/blood-2022-158097
Published: 2022
Journal Articles

One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Javier Munoz, MD, Andre H. Goy, MD, Frederick L. Locke, MD, Caron A. Jacobson, MD, Brian T. Hill, MD, John M. Timmerman, MD, Houston Holmes, Samantha Jaglowski, MD MPH, Ian W. Flinn, MD PhD, Peter A. McSweeney, MD, David B. Miklos, MD PhD, John M. Pagel, MD PhD, Marie José Kersten, MD PhD, Noel Milpied, Henry C.H. Fung, MD, Max S. Topp, MD, Roch Houot, MD PhD, Amer Beitinjaneh, MD MPH, MSc, Weimin Peng, PhD, Lianqing Zheng, PhD, John M. Rossi, MS, Swaminathan Murugappan, MD PhD, Ioana Kloos, MD, Patrick M. Reagan, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–22.
https://doi.org/10.1182/blood-2020-136382
Published: 2020
Journal Articles

Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Michael Wang, MD, John M. Rossi, MS, Javier Munoz, MD, Andre H. Goy, MD, Frederick L. Locke, MD, Patrick M. Reagan, MD, Caron A. Jacobson, MD, Brian T. Hill, MD, Houston Holmes, Samantha Jaglowski, MD MPH, Weimin Peng, PhD, Lianqing Zheng, PhD, Xiang Fang, PhD, Allen Xue, PhD, Ioana Kloos, MD, Adrian Bot, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29.
https://doi.org/10.1182/blood-2020-136831
Published: 2020
Journal Articles

Antimyeloma Effect of the Simultaneous Inhibition of MCL-1 (with S63845) and BCL-2 (with Venetoclax) in the Presence of the Microenvironment

Esperanza M Algarín, MSc, Andrea Díaz-Tejedor, Pedro Mogollón, Susana Hernández-García, Luis Corchete, Laura San-Segundo, Montserrat Martín-Sánchez, Lorena González-Méndez, Marie Schoumacher, Sébastien Banquet, Laurence Kraus-Berthier, Ioana Kloos, Ensar Halilovic, Heiko Maacke, Norma C. Gutierrez, MD PhD, Maria-Victoria Mateos, MD PhD, Teresa Paíno, Mercedes Garayoa, Enrique M. Ocio, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 954.
https://doi.org/10.1182/blood-2018-99-116075
Published: 2018
Journal Articles

Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML

Jessica M Salmon, PhD, Giovanna Pomilio, Donia M Moujalled, PhD, Sarah Macraild, Charis E Teh, PhD, Sewa Riajl, PhD, Adam Ivey, BSc, MSc, PhD, Tse-Chieh Teh, MD, Paul G Ekert, Laurence Kraus-Berthier, Ioana Kloos, Marie Schoumacher, Daniel Gray, Andrew H Wei, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1426.
https://doi.org/10.1182/blood-2018-99-117403
Published: 2018
Journal Articles

Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study

Vincent Ribrag, MD, Won Seog Kim, MD PhD, Reda Bouabdallah, MD, Soon Thye Lim, MBBS, MRCP, Bertrand Coiffier, Zakia Felloussi, Ioana Kloos, Ying Luan, PhD, Thorsten Graef, MD PhD, Franck Morschhauser, MD
Journal: Blood
Blood (2015) 126 (23): 256.
https://doi.org/10.1182/blood.V126.23.256.256
Published: 2015
Journal Articles

Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients

Franck Morschhauser, MD, PhD, Louis Terriou, MD, Bertrand Coiffier, MD, PhD, Gilles Salles, MD, Ioana Kloos, MD, Nicolas Tavernier, PharmD, Stephane Depil, MD, PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2012) 120 (21): 3643.
https://doi.org/10.1182/blood.V120.21.3643.3643
Published: 2012